secwatch.observer — SEC 8-K summary
======================================

Issuer:     GRI Bio, Inc. (GRI)
CIK:        0001824293
Form:       8-K
Filed at:   2024-11-14T23:59:59+00:00
Accession:  0001824293-24-000153
Event type: earnings
Sentiment:  neutral
Materiality: 0.50
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

GRI Bio reports Q3 net loss of $6.3M; cash runway extended into mid Q1 2025
---------------------------------------------------------------------------

- Net loss of $6.3M for nine months ended Sep 30, 2024; R&D expenses $2.9M.
- Cash and cash equivalents $4.7M as of Sep 30, 2024.
- Raised $13.9M gross proceeds since start of 2024, extending runway into mid Q1 2025.
- Interim data from GRI-0621 Phase 2a biomarker study expected Q1 2025; topline Q2 2025.
- Preclinical data presented; Japan patent granted; Australian study authorization received.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1824293/000182429324000153/0001824293-24-000153-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1824293/000182429324000153/val-20241114.htm
  HTML page:      https://secwatch.observer/filing/0001824293-24-000153

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer